The collaboration combines Abbott′s glucose sensing technology with Omada Health's proprietary digital coaching platform to provide personalized care.
The contract will cover eligible members who are living with Type 1 or Type 2 diabetes, covering 5.3 million federal employees, retirees and their families.
The partnership will provide personalized diabetes support with the protection of life insurance and the potential to earn up to 25% in premium savings.
The device uses thermographic monitoring of a patient's feet to identify early onset of diabetic foot ulcers, which can lead to limb loss if not detected early.
This year, it is expected to exceed $742M, growing at an average CAGR of 50% annually.
The two companies will collaborate to create a new version of the BlueStar insulin management solution that integrates insulin data for Lilly insulins.
Partners offer app compatibility with Tempo Pen and Tempo Smart Button to help streamline diabetes management.